CME credits: 0.50

Valid until: 15-03-2024

Claim your CME credit at https://reachmd.com/programs/cme/altering-the-course-of-type-1-diabetes-prevention-trials/14287/

Autoantibody Screening to Identify Risk for Type 1 Diabetes
T1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.

=